Article

What We're Reading: Anthem Blue Cross Fined; Healthcare for the Homeless; J&J Versus FDA

Author(s):

California hands down millions in fines to Anthem Blue Cross; “street medicine” aims to bring healthcare to the homeless in Atlanta; Johnson & Johnson claims its baby powder is safe.

Anthem Blue Cross Tops the List of Most-Fined Insurers in California

Anthem Blue Cross in California was fined almost $9.6 million between January 2014 and November 2019 by the state’s Department of Managed Health Care (DMHC), according to California Healthline, for violations that included not covering out-of-network care that should have been covered and wrongly denying claims. That is close to 44% of all penalties for the period. In 2017 alone, Anthem was fined $5 million for letting customer issues drag on for too long, which was eventually negotiated down to $2.8 million and a promise to use $8.4 million for improvements. In total, DMHC has fined licensed health plans $73 million since 2000, its first year.

Compassion and Understanding Bring Healthcare to the Underserved

Mercy Care in Atlanta, Georgia, brings healthcare to the homeless on a daily basis, Kaiser Health News reports, spending close to $900,000 each year since 2013, when its street medicine program began. Outreach personnel include social workers, mental health specialists, and nursing students on 4-week rotations who strive to gain the trust of their often-stigmatized clientele before offering counseling, blood pressure measurements, and flu shots—among the many services they provide. In a non—Medicaid expansion state, Mercy Care hopes to prevent repeated visits to the emergency department, saving money in the process.

Asbestos Tests Come Up Negative for Johnson & Johnson

Following a voluntary October recall of 1 lot of its Baby Powder—33,000 bottles in the United States—Johnson & Johnson conducted 155 tests via 4 testing methods at 2 third-party labs, contesting claims by the FDA that the powder contains trace amounts of asbestos, according to Reuters. This follows testing also completed in October, with similar results. J&J states that the FDA’s results may be due to sample contamination or lab analyst error, possibly both. J&J has faced increasing scrutiny over the years from lawsuits over baby powder, opioids, and Risperdal, an antipsychotic, among others.

Related Videos
Molly Dean, MSW, Siftwell
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Annie Antar, MD, PhD, Johns Hopkins Medicine
1 expert is featured in this series.
Rachel Rohaidy, MD
Dr Chun Chao
Andrew Kuykendall, MD, Moffitt Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo